Human care company Elekta AB (STO:EKTAB.ST) announced on Monday that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received the CE mark, clearing the technology for commercial sales and clinical use in Europe.
According to the company, Unity has the potential to transform how clinicians treat cancer by enabling the delivery of the radiation dose while simultaneously visualising the tumour and surrounding healthy tissue with high-quality MR images.
Also, Unity integrates advanced tools that allow clinicians to adapt the patient's treatment to this current anatomical information.
Elekta added that although the Unity has CE mark, it is not available for commercial distribution or sale in the US.
Elekta's treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886